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To the Editor: 
Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections1. 
The risk of developing these infections increases when white blood cell (WBC) counts, particularly the 
absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant 
white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile 
neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia1 
(ANC<500/µL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, 
currently in approximately one in six of all chemotherapy patients2, and it is associated with a high rate of 
mortality3, where 11% of patients die after one or several hospitalizations4,5. In the US alone, the 
associated cost due to such hospitalizations accounts for $2.7B dollars annually2, contributing to up to 
40% of the total cost of cancer treatments6.  
Early detection of severe neutropenia can be key to preventing FN. Timely detection could enable 
preventive therapies, such as Granulocyte-Colony Stimulating Factors (GCSF)7 or prophylactic 
antibiotics, to be administered. Unfortunately, current neutrophil monitoring options are inadequate to 
monitor severe neutropenia with sufficient frequency to allow for early detection and therapy 
optimization. Their reliance on the extraction and analysis of blood samples, which requires trained 
medical oversight, typically limits this testing to clinical settings. Cost-effective high frequency 
monitoring of this parameter, therefore, requires a new method that can be used by outpatients with 
minimal risk. 
To address this unmet need, we propose the first non-invasive technology that can automatically screen 
patients for severe neutropenia without requiring blood draws, thus enabling patients to have more 
frequent access to this test. Our proposed non-invasive device is a compact microscopy system that can 
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acquire high-resolution, high-frame-rate videos of superficial capillaries (Figure S1)8, coupled with an 
automated software pipeline that can analyze those videos for a measurement of neutropenia. This design 
potentially opens the door to the use of such instrumentation in the patient’s home. We conducted a 
clinical study at two independent hospitals to assess the ability of our device and algorithm to detect 
severe neutropenia in chemotherapy patients undergoing standard therapy. In previously reported work8, 
we demonstrated an initial proof-of-concept of this principle using a small set of nailfold capillary video 
samples8, which were manually analyzed through visual inspection by human experts. Here, we further 
demonstrated and validated a fully automated software analysis pipeline and extended our results to a 
larger cohort of 44 patients.  
The individuals enrolled in our study were selected from patients undergoing high-dose chemotherapy 
followed by Autologous Stem Cell Transplantation (ASCT) at the Massachusetts General Hospital 
(MGH) Boston, MA, USA, or at Hospital Universitario La Paz (HULP), Madrid, Spain. This specific 
patient population was selected due to its clinical relevance and highly standardized regimen which 
allows for predictable evolution of neutrophil count dynamics, ensuring a transition from baseline values 
(ANC>500/µL) to severe neutropenia (ANC<500/µL), as well as an opportunity to acquire multiple video 
samples at different time points (Figure S2). The protocol was approved by the corresponding IRB boards 
for a total of 44 patients to be included in this study (Supplementary Methods). 
From the 44 enrolled subjects, video sessions containing at least one suitable capillary in their field of 
view were collected (Supplementary Methods) at different stages of the ASCT treatment (Figure S2). 
Specifically, a technical operator ensured that at least one capillary fulfilled the required quality criteria 
for analysis8. This resulted in a total of 115 imaging sessions from 42 subjects, with an average of three 
sessions per subject. Each imaging session is associated with a reference blood test performed by the 
gold-standard clinical-laboratory analyzer whose values, including the reference ANCs, are provided in 
the Supplementary Methods (Figure S3). To confirm the findings of our previous work correlating the 
number of capillaries analyzed with the classification accuracy8, we evaluated the diagnostic performance 
of our automatic pipeline on three distinct sets of imaging sessions: those that had at least one suitable 
capillary (all 115 imaging sessions from all 42 patients), at least two (100 imaging sessions from 38 
patients), or at least three (89 sessions from 35 patients). 
Following the acquisition of these sessions using our clinical prototype8, an automated software pipeline 
composed of several processing steps (Supplementary Methods) was designed to analyze the raw videos. 
The analysis of each video session produced a separate data point consisting in a unitless “Leuko Index”, 
which was used to classify severe-neutropenic cases (ANC<500/µL) from the rest (ANC>500/µL). To 
produce this index, our pipeline first detected nailfold capillaries in the corresponding video session, then 
counted passing optical-absorption gaps —which as discussed in Bourquard et al 20188 can be considered 
as proxies of flowing neutrophils — inside these capillaries, and finally averaged the individual capillary 
counts into one single value. Results were then compared against the gold-standard ANC values to 
determine performance in separating severely neutropenic patients (ANC<500/µL) from the rest 
(ANC>500/µL), giving the opportunity to calculate the rate of correctly-classified severe neutropenia 
cases (true positives) against the rate of false alarms (false positives).   
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The classification performance for all imaging sessions, with at least three suitable capillaries detected, 
yielded an Area Under the Curve (AUC)9 of 0.95 (Figure 1). The use of all imaging sessions with at least 
one suitable capillary yielded an AUC of 0.91 (Figure S4), whereas those containing at least two suitable 
capillaries yielded an AUC of 0.94 (Figure S5). The intra-measurement agreement of our method when 
using only one, two or three capillaries per imaging session was shown to increase as more capillaries 
were used (87% agreement when using 1 vs. 2 capillaries and 91.4% agreement when using 2 vs. 3 
capillaries), see Figure S6. Also, the classification performance improved with the amount of analyzed 
capillaries per session, with the percentage agreement increasing from 69.8% to 90.9% (Figure S6), which 
also corroborates previous results8.  
 
<Figure 1> 
 
Caption: Figure 1: (Left) Non-invasive imaging sessions (red and blue markers), acquired from 
chemotherapy patients in our study, were automatically analyzed by our software pipeline to yield a 
“Leukoindex” result which can be used to perform a classification with respect to the corresponding 
gold-standard ANC values obtained from blood tests. Each classification result is associated either 
with a severe-neutropenic reference state (ANC<500; red markers) or above (ANC>500; blue 
markers). Results corresponding to imaging sessions containing at least three suitable capillaries 
are shown. (Right) Receiver Operating Characteristic (ROC) curve associated with this classification 
(AUC = 0.95, 35 patients, and N =89 imaging sessions). 
     
These results demonstrate, for the first time, that our non-invasive optical system (Figure S1), coupled 
with the proposed automated video analysis pipeline (Figure S7), is able to detect severe neutropenia with 
high accuracy in a patient cohort showing various degrees of ANC values (Figure S3), without the need 
for a blood draw. Future work includes the refinement of the device hardware to increase the number of 
suitable capillaries detected in a single session. The current analysis methods may also be adapted in the 
future to perform quantitative ANC measurements or differential detections of WBC subtypes.   
 
Overall, this work demonstrates that patients can be screened for severe neutropenia automatically and 
non-invasively without the need to draw blood. Our non-invasive blood analysis method opens the door 
to frequent, precise and personalized management of patients at risk for febrile neutropenia. 
 
Acknowledgments  
The authors thank the Madrid-MIT M+Visión Consortium, the Catalyst program, and MIT linQ for their 
support and guidance in developing this project. They thank Martha L. Gray, Benjamin J. Vakoc, 
Timothy P. Padera, and all other MIT linQ faculty members who provided invaluable feedback and 
advice through regular working-group sessions and meetings. This work was supported by the NIH NCI 
SBIR Program (award no. 1R43CA228920-01A1); the Comunidad de Madrid through the Madrid-MIT 
M+ Visión Consortium; the Center For Future Technologies in Cancer Care through Grant NIH U54 
(award no. 4U54EB015403-05); the Wallace H. Coulter Foundation at BU; the Deshpande Center for 
Technological Innovation; the MIT Sandbox Innovation Fund; and the M+Visión EU FP7-PEOPLE-
2011-COFUND Program of the  Fundación Madri+d (Comunidad de Madrid). 
 
This article is protected by copyright. All rights reserved.
Authorship Contributions 
APT collected and analyzed data, implemented critical elements of the software pipeline, and wrote 
substantial sections of the manuscript; IB analyzed data, provided substantial support in data 
interpretation, and provided substantial support in software development and quality control; MJLC 
supervised the development of the proposed pipeline and contributed in the analysis and interpretation of 
results; TV analyzed data, conceived the software-pipeline structure, and implemented critical elements of 
the software pipeline; ASF collected data, analyzed results, and provided substantial support on data 
interpretation; LS, NJD, and AMB provided technical advice and contributed in the manuscript revision; 
CC, KH, MFU, CDR, and BV made substantial contributions to patient recruitment and data acquisition; 
YBC and EPH made substantial contributions to the conception and design of our clinical study; CCG 
and AB made substantial contributions to the conception of the initial technological concept, the design of 
the clinical study, experimental framework, data acquisition, the analysis and interpretation of data, and 
supervised the manuscript writing and the overall development of the proposed method; All authors 
revised the article critically for important intellectual content and approved of its submission.  
 
Disclosure of Conflict of Interest 
CCG, IB, AB, and ASF have an issued patent on the proposed technology under patent number US 
9,984,277 B2 and title “Systems, Apparatus, and Methods for Analyzing Blood Cell Dynamics”. APT, 
IB, ASF, AB, and CCG report honoraria, financial support from, and current employment by Leuko Labs 
Inc. to conduct this research. IB, ASF, CCG, and AB hold equity in Leuko Labs Inc. All other authors 
have nothing to declare. 
 
REFERENCES 
 
1. Meza L, Baselga J, Holmes FA, Liang B, Breddy J, Group PS. Incidence of febrile neutropenia (FN) is 
directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am 
Soc Clin Oncol. 2002. p. 255b. 
2. Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, 
United States, 2012. J Oncol Pract. 2017;13(6):e552–e561. 
3. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer 
Netw JNCCN. 2009 Jan;7(1):99–108.  
4. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated 
with febrile neutropenia in adult cancer patients. Cancer. 2006 May 15;106(10):2258–2266. 
5. Lyman GH, Poniewierski MS, Crawford J, Dale DC, Culakova E. Cost of hospitalization in patients 
with cancer and febrile neutropenia and impact of comorbid conditions. Am Soc Hematology; 2015. 
6. Schuette HL, Tucker TC, Brown ML, Potosky AL, Samuel T. The costs of cancer care in the United 
States: implications for action. Oncol Williston Park N. 1995 Nov;9(11 Suppl):19–22.  
7. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G. 
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in 
patients with small-cell lung cancer. N Engl J Med. 1991 Jul 18;325(3):164–170.  
8. Bourquard A, Pablo-Trinidad A, Butterworth I, Sánchez-Ferro Á, Cerrato C, Humala K, Fabra Urdiola 
M, Del Rio C, Valles B, Tucker-Schwartz JM, Lee ES, Vakoc BJ, Padera TP, Ledesma-Carbayo MJ, 
This article is protected by copyright. All rights reserved.
Chen Y-B, Hochberg EP, Gray ML, Castro-González C. Non-invasive detection of severe neutropenia in 
chemotherapy patients by optical imaging of nailfold microcirculation. Sci Rep. 2018 Mar 28;8(1):5301.  
9. Lasko TA, Bhagwat JG, Zou KH, Ohno-Machado L. The use of receiver operating characteristic curves 
in biomedical informatics. Journal of biomedical informatics. 2005 Oct 1;38(5):404-15 
  
This article is protected by copyright. All rights reserved.
 This article is protected by copyright. All rights reserved.
